Author's reply:
Sir, I thank Messrs Chell and Hunter for their letter. It contains an important message and I recognised the significance of the medicolegal aspect in my comments.
Any system of screening for DDH in the UK will have limitations in effectiveness or implementation with inevitable medicolegal consequences.
It is only by reassessment of our guidelines for good practice that we will arrive at practicable and fair standards, robust and clear enough to satisfy patients, clinicians and lawyers alike.
D. H. A. JONES, FRCS
The Hospital for Sick Children London, UK.
Thromboprophylaxis -which treatment for which patient?
Sir, In his Editorial entitled 'Thromboprophylaxis -which treatment for which patient?' in the May 2000 issue, Professor Prentice 1 states that the results of the Pulmonary Embolism Prevention (PEP) trial 2 showed that aspirin produced significant reductions in total thromboembolism, total pulmonary embolism (PE), fatal PE and deep-vein thrombosis (DVT), as compared with a placebo. While this is true for the main body of the study, in which patients with fractures of the hip were assessed, it is manifestly untrue for the subgroup of 4000 patients who had replacement arthroplasties. In these latter patients, there were eight cases of PE in those given aspirin and eight in those given placebo; there was also no significant difference in the incidence of DVT (15 cases v 19). In terms of overall mortality, there were nine deaths in the aspirin group and 11 in the placebo group.
In a symposium devoted to prophylaxis after total hip replacement, it is therefore misleading to state that "aspirin reduces the risk of clinical PE and DVT by at least one-third, and of fatal PE by about one-half", without noting that these figures relate only to patients with fractures of the hip. The PEP study showed no such effectiveness after replacement arthroplasty, and indeed in these patients the only reasonable conclusion is that aspirin is no more effective than placebo as a thromboprophylactic agent. 
Author's reply:
Sir, The findings of the Pulmonary Embolism Prevention (PEP) trial, 1 together with those of the previous meta-analysis of antiplatelet trials, demonstrate clearly that daily aspirin for a few weeks can reduce the risks of deep-vein thrombosis and pulmonary embolism by at least a third in a wide range of patients. It would be inappropriate to suggest, as Dr Thomas does, that the lack of significant result among the relatively small number of patients in the arthroplasty subgroup of the PEP trial, considered on its own, shows that aspirin is not effective among patients undergoing elective arthroplasty. As discussed in my Editorial, the hazard ratio for venous thromboembolism of 0.81 (95% CI 0.47 to 1.42) among elective arthroplasty patients allocated aspirin was entirely compatible with that of 0.64 (95% CI 0.5 to 0.81) among patients with fracture of the hip (heterogeneity between proportional reductions p = 0.04). Furthermore, in the previous meta-analysis, antiplatelet therapy 2 produced similar proportional reductions in deep-vein thrombosis and in pulmonary embolism among patients undergoing cold and traumatic orthopaedic surgery.
The problem with using results from particular subgroups considered on their own may be illustrated by analysis of the evidence for heparin thromboprophylaxis. 3 In the subgroup of orthopaedic patients included in the meta-analysis of heparin trials, pulmonary embolism was recorded in 52 patients allocated heparin and in 49 of those allocated placebo. These event rates were clearly not significantly different. Instead, orthopaedic surgeons who use heparin rely, in a large part, on the significant reduction in venous thromboembolism observed with heparin in patients undergoing all types of surgery. In a similar manner, given the strength of the evidence now available, it would be reasonable for orthopaedic surgeons to consider the use of aspirin as a thromboprophylactic agent.
C. R. M. PRENTICE, MD, FRCP University of Leeds, UK. 
Pulmonary Embolism Prevention

The Baumann procedure for fixed contracture of the gastrosoleus in cerebral palsy
Sir, I read with interest the article by Saraph et al 1 entitled 'The Baumann procedure for fixed contracture of the gastrosoleus in cerebral palsy' in the May 2000 issue. The authors are to be congratulated on providing prospective, objective information as to the outcome of this method of gastrocnemius lengthening. However, when they compare the Baumann method with the traditional methods of aponeurotic lengthening described by Vulpius and Strofel 2 , Baker 3 and Strayer, 4 they comment adversely on the advisability of operating on the musculotendinous junction because of potential damage to the 'growth plate' of the muscle. A careful reading of the paper by Ziv et al 5 gives the relative percentage contributed to longitudinal growth by various parts of the muscle-tendon unit. Although a substantial amount of longitudinal growth comes from the area of the musculotendinous junction, no histological or other evidence has ever been advanced to support the idea of a musculotendinous 'growth plate'. Until this information is provided, this remains a theoretical rather than an established or practical concept. In any case, the diagrams in Figure 3 illustrate that the site of surgery is in the conjoined gastrosoleus fascia and not at the musculotendinous junction.
Secondly, the comment that "a review of the literature shows that there is higher incidence of recurrence and overlengthening after lengthening of the tendon than the aponeurotic lengthening" cannot go unchallenged. It is difficult to compare the results of aponeurotic muscle lengthening with those of lengthening of tendo Achillis from the retrospective studies which dominate the literature. 6 To date there have been no randomised clinical trials. On balance, however, the literature suggests that the type of cerebral palsy is more important than the type of surgery in determining the risk of recurrent equinus versus calcaneus. Children with hemiplegia are more likely to have recurrent equinus, and children with diplegia to have calcaneus.
Given that the study population in this report was made up of children with diplegia, lengthening of tendo Achillis is much more likely to be associated with overlengthening than recurrent equinus, as we have confirmed. 
Sir,
We thank Professor Kerr Graham for his comments. We agree that no histological evidence has been presented in the paper by Ziv et al, 1 but they did report that 45% of the muscle growth occurs at the musculotendinous junction and it cannot be refuted that a major part of the growth takes place in this area.
It is true that the aponeurotic lengthening procedures have been described at the conjoined gastrosoleus fascia and not at the musculotendinous junction, but the proximity to this junction presents a possible risk of surgical injury to the junction as mentioned in the legend to Figure 3 in our paper.
In reviewing the three studies in which different methods of triceps lengthening are compared, two had a mixed patient population of hemiplegics and diplegics and the outcome was not evaluated separately for both.
2,3 Sharrard and Bernstein 4 , however, found a higher recurrence after lengthening of tendo Achillis in diplegics (33%) as compared with hemiplegics (27%). The recurrence after aponeurotic lengthening was higher in hemiplegics than diplegics in their series.
We agree that the recurrence/overlengthening rates in diplegic and hemiplegic children will remain controversial until randomised clinical trials with a comparable patient population and type of involvement are presented. Our observations are based on the literature which we reviewed, as shown in Table IV . Since these papers have, however, presented mixed groups of hemiplegics and diplegics, it is possible that the conclusions from our literature review may not hold true for an isolated group of hemiplegic or diplegic patients.
The anatomical and mechanical merits of the Baumann procedure remain theoretical. 5 Long-term comparative studies with different methods of lengthening (aponeurotic, tendon lengthen-
Implantation of a soft-tissue expander before operation for club foot in children
Sir, We read with interest the article in the May 1999 issue by Roposch, Steinwender and Linhart 1 entitled 'Implantation of a soft-tissue expander before operation for club foot in children'.
In the introduction the authors state that primary skin closure after surgery for club foot can be difficult, and they therefore suggest the use of soft-tissue expanders before surgery to facilitate this. We would like to raise two points in relation to this.
Experience with the Cincinnati incision has shown that it is not necessary to achieve primary wound closure, as partially closed wounds heal well by secondary intention, with cosmetically acceptable scars and no significant complications. 2, 3 In relapsed and neglected club feet, the Ilizarov system facilitates adequate correction without the need for extensive soft-tissue dissection and the requirement for soft-tissue expansion. conclusions of our study. This was recently confirmed in a presentation by Bhandari, McKee and Schemitsch.
1 They performed a meta-analysis of the four prospective, randomised trials with intramedullary nails. Three involved reamed, locked intramedullary nails but they also included Dr Rodriguez-Merchan's study with an unreamed, unlocked, intramedullary device.
The pooled data (with 195 patients) showed that there was a significant difference in the rate of reoperation (risk reduction 62%, p = 0.02) and in the incidence of shoulder problems (risk reduction 78%, p = 0.004). When the confidence intervals for these primary outcomes are considered, all of the studies are similar, with a trend towards plates being better than intramedullary devices. It is not until all of the data are pooled, however, that the statistics become significant. Dr Bhandari and his co-authors will almost certainly be publishing the study and their conclusion is significant in that they state that the reduction of risk of secondary surgery is large enough to indicate that future trials in this area may be a poor investment of resources. There was no difference in the rate of nonunion, infection or injury to the radial nerve between the groups with either plates or nails in the published studies. This is a good example of the problems which may be encountered in small clinical studies and indicates the value of pooling data and the need for power calculations when studies report no statistical difference between treatment groups. 
Wound infection in hip and knee arthroplasty
Sir, I read with interest the article in the May 2000 issue by Gaine et al 1 entitled 'Wound infection in hip and knee arthroplasty'. Recent media attention to rising rates of nosocomial infection in British hospitals makes the paper most topical. Although the article was well presented and discussed, I would seriously question the safety of exposing wounds, especially in the early postoperative period. Airborne bacterial infection during this prospective trial will inevitably have caused some of the infections. More frequent exposure of inflamed wounds will have added to this risk.
In the 1950s, the late Professor Robin Pilcher, at University College Hospital, had to resort to encasing his operation wounds in plaster-of-Paris to convince staff that routine exposure of all wounds for inspection on daily ward rounds was both dangerous and unnecessary. The immediate reduction in wound sepsis after his radical action served to vindicate his beliefs fully.
It seems that we have forgotten the basic principles of crossinfection.
